Internal Medicine, Medical Oncology · Seattle, WA
NPI
1053358671
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
825 Eastlake Ave E
Seattle, WA, 98109
Phone (206) 228-1000
Groups this clinician bills Medicare through
Medicare paid, 2024
$4,431
60 services
Medicare patients, 2024
23
Average age 65
Drug cost, 2024
$349K
95 prescriptions
Company payments, 2025
$80K
From 11 companies
Medicare prescription drug claims, 2024
In 2024, the drug Vijayakrishna K Gadi prescribed most often to Medicare patients was Votrient (Pazopanib Hcl), with 24 prescriptions and refills. In total Vijayakrishna K Gadi wrote 95 Medicare prescriptions that cost $349K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-05.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Votrient Pazopanib Hcl | 24 | 24 | Under 11 | $316K |
| Tamoxifen Citrate Generic | 16 | 48 | Under 11 | $191 |
| Anastrozole Generic | 12 | 32 | Under 11 | $368 |
Brand drugs: 24 claims; generic drugs: 71 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vijayakrishna K Gadi $80K ($70K in general payments such as food, travel and fees and $10K for research) from 11 companies. The largest payer was Gilead Sciences, Inc. with $20K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 27 | $20K |
| Novartis Pharmaceuticals Corporation NVS | 11 | $17K |
| Puma Biotechnology, Inc. PBYI | 10 | $16K |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $11K |
| Pfizer Inc. PFE | 10 | $6,802 |
| Genentech USA, Inc. ROG.SW | 3 | $4,121 |
| Daiichi Sankyo Inc. 4568.T | 3 | $2,665 |
| TerSera Therapeutics LLC | 3 | $1,572 |
| Stemline Therapeutics Inc. | 7 | $421 |
| Kite Pharma, Inc. GILD | 3 | $231 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.